CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G–CSF

Fabritiis, Paolo de; Iori, Anna Paola; Mengarelli, Andrea; Gozzer, Maria; Ferrazza, Giancarlo; Propris, Maria Stefania De; Romano, Atelda; Arcese, William

doi:10.1046/j.1537-2995.2001.41020190.x

Cited by 23 publications

(17 citation statements)

References 28 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, apheresis procedures are started on day 4 or 5 [12,14,15] and the majority of normal donors require only one apheresis for the collection of a target CD34+ cell dose of 4 · 10 6 per kg of recipient body weight. However, a fraction of healthy donors do not provide effective mobilization, and procurement of the target CD34+ cell dose may require multiple procedures or may not be achieved despite daily apheresis [2,9].…”

Section: Resultsmentioning

confidence: 99%

Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

et al. 2006

View full text Add to dashboard Cite

No specific characteristics have been identified as predictors of peripheral blood stem cells (PBSC) mobilization in healthy donors. In this study, clinical characteristics and laboratory data for 122 healthy donors who underwent apheresis on day 5 of treatment with recombinant granulocyte colony-stimulating factor (G-CSF) were retrospectively analyzed for correlations with CD34(+) cell mobilization. The variables that were analyzed included age, sex, body weight, basal complete blood count, and maximum white blood count (WBC) before apheresis, G-CSF type, and dosage. Median age and body weight were 42.5 years (range 16-65) and 72.5 kg (range 47-121), respectively. By univariate analysis, male sex (P = 0.007), body weight (< or = 70 vs. >70 kg, P = 0.04), and donor's age (< or = 50 vs. > 50 years; P = 0.015) were correlated with the number of CD34(+) cells mobilized. By multivariate analysis, donor's age and male sex were the only two variables that significantly predicted a high CD34(+) cell level. In conclusion, our data suggest that male sex and younger age are the only factors that significantly affect CD34(+) mobilization in healthy donors.

show abstract

Section: Resultsmentioning

confidence: 99%

Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

et al. 2006

View full text Add to dashboard Cite

show abstract

“…With the s.c. schedule, it takes 4-6 days to reach optimum mobilization. 12,13 Using this schedule, male sex, young age (ie o38 or o40), rhG-CSF given twice daily(ie 5 mg/kg, bid), and a high rhG-CSF dose (ie 20-24 mg/kg) were reported, 2,4,5,12 as factors favoring increased mobilization, but other reports have failed to confirm these associations. 3,12 In our antagonist results in mobilization of progenitors to the blood.…”

Section: Discussionmentioning

confidence: 94%

A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors

Lee

Mun²,

Nam³

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of CD34 þ cells in the c.i.v. and s.c. groups increased maximally at day 3 and 5, respectively, when compared with the steady-state (day 0) level. Peak CD34 þ cell levels were achieved on day 3 in the c.i.v. group, with more rapid results than in the s.c. group (49.3/ ll vs 35.9/ll, P ¼ 0.043). Plasma rhG-CSF levels declined progressively during mobilization in each group as the WBC increased. The serum level of rhG-CSF did not correlate with CD34 þ cell counts in the peripheral blood. Toxicity profiles in the c.i.v. and s.c. groups were similar. Each regimen was effective in successfully mobilizing the target CD34 cell number.

show abstract

“…Multiple studies have been conducted to determine the optimal dosing and frequency of G‐CSF administration for PBSC mobilization. Currently, the most common approach is to treat the donor at a dose of 10‐16 µg/kg/day with expected maximal mobilization occurring between Days 4 and 6 10 . One study compared G‐CSF doses of 10 µg/kg versus 16 µg/kg in 90 healthy allogeneic donors with a greater proportion of patients achieving the collection target of >5.0 × 10 6 CD34 + cells/kg in the 16 µg/kg arm (61% vs. 45%) 11 .…”

Section: Cell Sources For Allogeneic Hsctmentioning

confidence: 99%

Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics

2011

View full text Add to dashboard Cite

The field of hematopoietic stem cell transplantation (HSCT) has overcome many obstacles that have led to our current clinical ability to utilize cells collected from marrow, mobilized peripheral blood, or umbilical cord blood for the treatment of malignant and nonmalignant hematologic diseases. It is in this context that it becomes evident that future progress will lie in our development of an understanding of the biology by which the process of HSCT is regulated. By understanding the cellular components and the mechanisms by which HSCT is either enhanced or suppressed it will then be possible to design therapeutic strategies to improve rates of engraftment that will have a positive impact on immune reconstitution post-HSCT. In this review we focus primarily on allogeneic hematopoietic stem cell transplantation (allo-HSCT), the current challenges associated with allo-HSCT, and some developing strategies to improve engraftment in this setting.

show abstract

CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G–CSF

Cited by 23 publications

References 28 publications

Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)

A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors

Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics

Contact Info

Product

Resources

About